Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain
- 1 March 1996
- journal article
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 103 (3) , 315-329
- https://doi.org/10.1007/bf01271243
Abstract
Decreased reduced glutathione (GSH) levels are an early marker of nigral cell death in Parkinson's disease. Depletion of rat brain GSH by intracerebroventricular administration of buthionine sulphoximine (BSO) potentiates the toxicity of 6-hydroxydopamine (6-OHDA) to the nigrostriatal pathway. We have investigated whether thioctic acid can replenish brain GSH levels following BSO-induced depletion and/or prevent 6-OHDA induced toxicity. Administration of BSO (2 × 1.6 mg ICV) to rats depleted striatal GSH levels by upto 75%. BSO treatment potentiated 6-OHDA (75 μg ICV) toxicity as judged by striatal dopamine content and the number of tyrosine hydroxylase immunoreactive cells in substantia nigra. Repeated treatment with thioctic acid (50 or 100mg/kg i.p.) over 48h had no effect on the 6-OHDA induced loss of dopamine in striatum or nigral tyrosine hydroxylase positive cells in substantia nigra. Also thioctic acid treatment did not reverse the BSO induced depletion of GSH or prevent the potentiation of 6-OHDA neurotoxicity produced by BSO. Thioctic acid (50mg or 100mg/kg i.p.) alone or in combination with BSO did not alter striatal dopamine levels but increased dopamine turnover. Striatal 5-HT content was not altered by thioctic acid but 5-HIAA levels were increased. Under conditions of inhibition of GSH synthesis, thioctic acid does not replenish brain GSH levels or protect against 6-OHDA toxicity. At least in this model of Parkinson's disease, thioctic acid does not appear to have a neuroprotective effect.Keywords
This publication has 35 references indexed in Scilit:
- α-lipoic acid prevents buthionine sulfoximine-induced cataract formation in newborn ratsFree Radical Biology & Medicine, 1995
- Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal gangliaAnnals of Neurology, 1994
- Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamateEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- An immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's diseaseAnnals of Neurology, 1994
- Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body diseaseAnnals of Neurology, 1994
- Lipoic and Dihydrolipoic Acids as Antioxidants. a Critical EvaluationFree Radical Research, 1994
- Oral glutathione increases tissue glutathione in vivoChemico-Biological Interactions, 1991
- Intracerebroventricular Administration of l‐Buthionine Sulfoximine: A Method for Depleting Brain GlutathioneJournal of Neurochemistry, 1989
- Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's DiseaseJournal of Neurochemistry, 1989
- Reduction of Brain Glutathione by l-Buthionine Sulfoximine Potentiates the Dopamine-Depleting Action of 6-Hydroxydopamine in Rat StriatumJournal of Neurochemistry, 1989